ResearcherUniformed Services University of the Health SciencesActive in the last 2 years
Daniel William Nelson
Matched on ORCID iD 0000-0003-1555-819X; OpenAlex author ID A5090437483. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers
Papers 8
- Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. Co-author DOI 10.1002/jso.27466↗
- The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on response to neoadjuvant therapy. Co-author DOI 10.1002/jso.27689↗
- Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. Last author DOI 10.1245/s10434-022-12908-z↗
- ASO Author Reflections: The Complexity of the Volume-Outcome Relationship in Pancreatic Cancer. First author DOI 10.1245/s10434-022-12920-3↗
- Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-023-13758-z↗
- Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. Co-author DOI 10.1245/s10434-022-11800-0↗
- ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-022-11878-6↗
- Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/ott.s311661↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy J. Vreeland · 7 shared papers, 2021–2024 · strength 1.22
- Paper ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancr… DOI 10.1245/s10434-022-11878-6↗
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Elizabeth L. Carpenter · 6 shared papers, 2022–2024 · strength 1.10
- Paper ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancr… DOI 10.1245/s10434-022-11878-6↗
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Phillip M. Kemp Bohan · 5 shared papers, 2022–2024 · strength 1.07
- Paper ASO Author Reflections: The Complexity of the Volume-Outcome Relationship in Pancreatic Cancer. DOI 10.1245/s10434-022-12920-3↗
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Alexandra M. Adams · 6 shared papers, 2021–2024 · strength 1.00
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Anne E. O’Shea · 5 shared papers, 2021–2024 · strength 0.85
- Paper ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancr… DOI 10.1245/s10434-022-11878-6↗
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Patrick M. McCarthy · 4 shared papers, 2021–2024 · strength 0.62
- Paper The benefit of adjuvant chemotherapy following pancreaticoduodenectomy for pancreatic adenocarcinoma depends on respons… DOI 10.1002/jso.27689↗
- Paper Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. DOI 10.1002/jso.27466↗
- Paper Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. DOI 10.1245/s10434-022-11800-0↗
- Holly V. Spitzer · 2 shared papers, 2023 · strength 0.37
- Paper Impact of Mediating and Confounding Variables on the Volume-Outcome Association in the Treatment of Pancreatic Cancer. DOI 10.1245/s10434-022-12908-z↗
- Paper Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic… DOI 10.1245/s10434-023-13758-z↗
- Franklin A. Valdera · 2 shared papers, 2024 · strength 0.36
- Robert Connor Chick · 2 shared papers, 2022–2024 · strength 0.31
- Robert W. Krell · 2 shared papers, 2021–2022 · strength 0.26
- Paper Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. DOI 10.1245/s10434-022-11800-0↗
- Paper Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Duct… DOI 10.2147/ott.s311661↗
- Timothy Eric Newhook · 1 shared paper, 2024 · strength 0.19
- Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.18
- Ching-Wei David Tzeng · 1 shared paper, 2023 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.